Advertisement
Advertisement
XLO
Xilio Therapeutics, Inc. Common Stock
9.17
USDSponsored
-0.10
-1.08%
Aug 07, 15:59 UTC -4
Closed
After-Market
9.25
+0.08
+0.86%
XLO Earnings Reports
Positive Surprise Ratio
XLO beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On May 12, 2026, XLO reported earnings of -0.57 USD per share (EPS) for Q1 26, beating the estimate of -0.66 USD, resulting in a 12.99% surprise. Revenue reached 12.65 million, compared to an expected 8.61 million, with a 46.98% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Xilio Therapeutics, Inc. Common Stock reported EPS of -$0.57, beating estimates by 12.99%, and revenue of $12.65M, 46.98% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved -- 0%, changed from $7.73 before the earnings release to $7.73 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement